In 301/448 (67.2%) thyroid cancer patients of European ancestry, the hazard ratio associated with the EZH2 eQTL modelled as an additive term was 0.64 (CI = 0.40 – 1.02), whereas the LPP eQTL was associated with a hazard ratio of 0.62 (CI = 0.45–0.93) in 356/443 (80.4%) prostate adenocarcinoma patients with European ancestry. This evidence concerns the gene EZH2 and prostate adenocarcinoma.